$1.09
+0.01(0.93%)
Mkt Cap $16M
$0.74
$4.74
52-Week Range
At A Glance
1
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
2
Most recently: of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1 (2026-03-03).
$16M
Market Cap
—
Revenue
-$5M
Net Income
Employees16
Fundamentals
How The Business Makes Money
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001173313
ISINUS00091F3047
CUSIP00091F106
Phone510 668 0881
Address44370 Old Warm Springs Boulevard, Fremont, CA, 94538, US
SEC EDGAR